Today's Announcement Discussion today seemed confused even though it was clearly pointed out how the funds will be used. If the company wishes to initiate the following before BTD & AA are awarded they will need capital to proceed. True a JV would be desirable a strong position of achievements on their own would demand a better deal for this company in such an arrangement. I see here a small company about to grow in size and strength, I am happy with what is about to unfold, cheers.
The Company intends to use the proceeds of the Financing for the following:
- Good Laboratory Practice (“GLP”) toxicology study for intravenous installation of Rutherrin® intended for the treatment of Non-Small Lung Cancer (“NSCLC”) and Glio-Blastoma Multiforme (“GBM”), a fast-growing and aggressive brain tumor.
- Advancement of Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study
- Working capital and general corporate purposes